Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer.
Sonya Youngju ParkSae Jung NaMeena KumarCamila MosciMirwais WardakNorman KoglinSantiago BullichAndre MuellerMathias BerndtAndrew W StephensYong Mee ChoHanjong AhnSun Young ChaeHye Ok KimDae Hyuk MoonSanjiv Sam GambhirErik S MittraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
18F-FSPG is a promising tumor imaging agent for PET that seems to have favorable biodistribution and high cancer detection rate in patients with prostate cancer. Further studies are warranted to determine the diagnostic value for both initial staging and recurrence, and how it compares with other investigational radiotracers and conventional imaging modalities.